See more : Power Group Projects Corp. (PGPGF) Income Statement Analysis – Financial Results
Complete financial analysis of EVe Mobility Acquisition Corp (EVE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of EVe Mobility Acquisition Corp, a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- TOMY Company, Ltd. (7867.T) Income Statement Analysis – Financial Results
- Suzhou Good-Ark Electronics Co., Ltd. (002079.SZ) Income Statement Analysis – Financial Results
- First US Bancshares, Inc. (FUSB) Income Statement Analysis – Financial Results
- Tanmiah Food Company (2281.SR) Income Statement Analysis – Financial Results
- Vistas Media Acquisition Company Inc. (VMACU) Income Statement Analysis – Financial Results
EVe Mobility Acquisition Corp (EVE)
About EVe Mobility Acquisition Corp
EVe Mobility Acquisition Corp. focuses on effectuating a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. It intends to focus on the automotive and mobility industry. The company was incorporated in 2021 and is based in Wilmington, Delaware.
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Cost of Revenue | 1.05M | 0.00 |
| Gross Profit | -1.05M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 |
| SG&A | 1.05M | 397.45K |
| Other Expenses | 0.00 | 0.00 |
| Operating Expenses | 1.05M | 397.45K |
| Cost & Expenses | 1.05M | 397.45K |
| Interest Income | 3.68M | 0.00 |
| Interest Expense | 0.00 | 0.00 |
| Depreciation & Amortization | 3.68M | 236.56K |
| EBITDA | 2.63M | -397.45K |
| EBITDA Ratio | 0.00% | 0.00% |
| Operating Income | -1.05M | -397.45K |
| Operating Income Ratio | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.68M | 608.00 |
| Income Before Tax | 2.63M | -396.84K |
| Income Before Tax Ratio | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -236.56K |
| Net Income | 2.63M | -396.84K |
| Net Income Ratio | 0.00% | 0.00% |
| EPS | 0.08 | -0.01 |
| EPS Diluted | 0.08 | -0.01 |
| Weighted Avg Shares Out | 34.47M | 34.57M |
| Weighted Avg Shares Out (Dil) | 34.47M | 34.57M |
Evolva Provides Update on Stevia Collaboration and 2016 Preliminary Top-Line Numbers
REINACH, Switzerland--(BUSINESS WIRE)--Evolva (SIX: EVE) provides an update to shareholders on its collaboration with Cargill on the next-generation stevia sweetener, EverSweet™, and its preliminary, unaudited, 2016 top-line financials. Stevia update Evolva currently expects EverSweet™ to launch in 2018. During 2016...
Pivotal Evolva Stevia Sweetener Patent Receives US Notice of Allowance
REINACH, Switzerland--(BUSINESS WIRE)--Evolva (SIX:EVE) announces that it has received a Notice of Allowance for a pivotal patent application (US 2013/0171328) from the US Patent & Trademark Office covering the most commercially viable production method for manufacturing the best-tasting steviol glycosides....
Evolva Enters Partnership on Active Pharmaceutical Ingredients
REINACH, Switzerland--(BUSINESS WIRE)--Evolva (SIX: EVE) has entered into an agreement with a private US biotech venture to develop new production routes for a family of existing active pharmaceutical ingredients (“API”). Evolva will be responsible for the development of the production...
Evolva’s collaboration with US Navy to focus on resveratrol-based composites
REINACH, Switzerland--(BUSINESS WIRE)--Evolva’s (SIX:EVE) collaboration with the US Navy (NAVAIR research facility, China Lake, California) to develop novel composite materials is to focus on the development of a new class of structural composite materials engineered from a polymer resin matrix...
Evolva’s nootkatone enters NIH-sponsored studies to assess its effectiveness against mosquitoes that transmit Zika virus
REINACH, Switzerland--(BUSINESS WIRE)--Evolva (SIX:EVE) announces that the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will sponsor studies to test Evolva’s nootkatone against mosquitoes infected with Zika virus. The study will...
Evolva granted pivotal patent for commercial production of best-tasting fermentation-derived steviol glycosides
REINACH, Switzerland--(BUSINESS WIRE)--Evolva (SIX:EVE) announces that the European Patent Office has granted the Company patent number 2742142, intellectual property pivotal to the commercial expansion of and broader access to the best-tasting stevia-sweeteners made possible through the introduction of yeast fermentation-derived...
Evolva to Co-Develop Next-Generation Materials with US Navy
REINACH, Switzerland--(BUSINESS WIRE)--Evolva (SIX: EVE) announced that it has completed a Limited Purpose Cooperative Research and Development Agreement (CRADA) to support the joint development of novel advanced materials with the US Navy. The focus of the efforts supported by this...
Evolva gains exclusive license to develop and commercialise nootkatone globally for pest control
REINACH, Switzerland--(BUSINESS WIRE)--Evolva (SIX: EVE) announces that it has just signed a license agreement with the US Centers for Disease Control and Prevention (CDC) that grants Evolva the exclusive worldwide patent rights to develop and commercialise nootkatone for the control...
Evolva Expanding Its nootkatone Research with CDC to Include Mosquitoes That Transmit Zika and Other Viruses
REINACH, Switzerland--(BUSINESS WIRE)--Evolva (SIX:EVE) announces that it is expanding its current work with the US Centers for Disease Control (CDC) to research nootkatone’s effectiveness in tick-control to include an additional focus on mosquitoes, including those that transmit Zika, chikungunya, dengue,...
Evolva Achieves Milestones in Flavour & Fragrance Alliance with Takasago
REINACH, Switzerland--(BUSINESS WIRE)--Evolva (SIX:EVE) today announces reaching the first technical milestones under the multi-year R&D alliance with Takasago. This achievement, taking place three months ahead of schedule, prompts a total milestone payment of CHF 1 million to Evolva. The aim...
Source: https://incomestatements.info
Category: Stock Reports